...
首页> 外文期刊>BMC Systems Biology >Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model
【24h】

Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model

机译:簇牛顿法基于约束的扰动分析:基于伊立替康全身生理学药代动力学模型的个性化参数估计的案例研究

获取原文
           

摘要

Drug development considering individual varieties among patients becomes crucial to improve clinical development success rates and save healthcare costs. As a useful tool to predict individual phenomena and correlations among drug characteristics and individual varieties, recently, whole-body physiologically based pharmacokinetic (WB- PBPK) models are getting more attention. WB-PBPK models generally have a lot of drug-related parameters that need to be estimated, and the estimations are difficult because the observed data are limited. Furthermore, parameter estimation in WB-PBPK models may cause overfitting when applying to individual clinical data such as urine/feces drug excretion for each patient in which Cluster Newton Method (CNM) is applicable for parameter estimation. In order to solve this issue, we came up with the idea of constraint-based perturbation analysis of the CNM. The effectiveness of our approach is demonstrated in the case of irinotecan WB-PBPK model using common organ-specific tissue-plasma partition coefficients (Kp) among the patients as constraints in WB-PBPK parameter estimation. We find strong correlations between age, renal clearance and liver functions in irinotecan WB-PBPK model with personalized physiological parameters by observing the distributions of optimized values of strong convergence drug-related parameters using constraint-based perturbation analysis on CNM. The constraint-based perturbation analysis consists of the following three steps: (1) Estimation of all drug-related parameters for each patient; the parameters include organ-specific Kp. (2) Fixing suitable values of Kp for each organ among all patients identically. (3) Re-estimation of all drug-related parameters other than Kp by using the fixed values of Kp as constraints of CNM. Constraint-based perturbation analysis could yield new findings when using CNM with appropriate constraints. This method is a new technique to find suitable values and important insights that are masked by CNM without constraints.
机译:考虑患者个体差异的药物开发对于提高临床开发成功率和节省医疗费用至关重要。作为预测个体现象和药物特性与个体品种之间相关性的有用工具,最近,基于全身生理学的药代动力学(WB-PBPK)模型越来越受到关注。 WB-PBPK模型通常具有许多与药物相关的参数,需要对其进行估计,并且由于所观察到的数据有限,因此很难进行估计。此外,WB-PBPK模型中的参数估计在应用于个体临床数据(如每个患者的尿液/粪便药物排泄)时可能会导致过拟合,其中簇牛顿法(CNM)适用于参数估计。为了解决这个问题,我们提出了基于约束的CNM扰动分析的思想。在伊立替康WB-PBPK模型中,使用患者之间的常见器官特异性组织-血浆分配系数(Kp)作为WB-PBPK参数估计的约束条件,证明了我们方法的有效性。通过使用基于约束的扰动分析对CNM观察强收敛药物相关参数的优化值分布,我们发现伊立替康WB-PBPK模型具有个性化生理参数时,年龄,肾脏清除率和肝功能之间存在很强的相关性。基于约束的扰动分析包括以下三个步骤:(1)估计每个患者的所有与药物相关的参数;参数包括器官特异性Kp。 (2)在所有患者中相同地固定每个器官的Kp合适值。 (3)使用Kp的固定值作为CNM的约束条件,重新估计除Kp以外的所有与药物相关的参数。当使用具有适当约束的CNM时,基于约束的扰动分析可能会产生新的发现。此方法是一种新技术,可以找到不受约束的CNM掩盖的合适值和重要见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号